ORPHA:589830
Adult-onset Steinert myotonic dystrophy
Also known as: Adult-onset Steinert disease · Adult-onset myotonic dystrophy type 1
Publications
43
42.4th percentile
Trials
0
Interventional, condition-specific
Researchers
238
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0035649
- UMLS:C5680309
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
43 matched papers (28 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 63 for broader category myotonic dystrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
43
43 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
43 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
28 in the last 10 years · high confidence · 42.4th percentile (publications denominator)
Phrase hits: 43 · MeSH hits: 0
Who's working on it?
238
Distinct author names in 43 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Gutmann L7 papers · 2023
Department of Psychiatry (E.v.d.P., T.R.K., P.N.), Department of Radiology (V.M.), and Department of Neurology (L.G.), University of Iowa Hospitals and Clinics; and Institute of Molecular, Cell and Systems Biology (S.A.C., D.M.), University of Glasgow, Scotland, United Kingdom.
Papers in Europe PMC - 02van der Plas E7 papers · 2023
Department of Psychiatry (E.v.d.P., T.R.K., P.N.), Department of Radiology (V.M.), and Department of Neurology (L.G.), University of Iowa Hospitals and Clinics; and Institute of Molecular, Cell and Systems Biology (S.A.C., D.M.), University of Glasgow, Scotland, United Kingdom.
Papers in Europe PMC - 03Dreyer P5 papers · 2026
Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
Papers in Europe PMC - 04Handberg C5 papers · 2026
National Rehabilitation Centre for Neuromuscular Diseases, Aarhus, Denmark.
Papers in Europe PMC - 05Koscik TR5 papers · 2023
Department of Psychiatry (E.v.d.P., T.R.K., P.N.), Department of Radiology (V.M.), and Department of Neurology (L.G.), University of Iowa Hospitals and Clinics; and Institute of Molecular, Cell and Systems Biology (S.A.C., D.M.), University of Glasgow, Scotland, United Kingdom.
Papers in Europe PMC - 06Monckton DG5 papers · 2023
Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Papers in Europe PMC - 07Nopoulos PC5 papers · 2023
Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA.
Papers in Europe PMC - 08Werlauff U5 papers · 2026
National Rehabilitation Centre for Neuromuscular Diseases, Aarhus, Denmark.
Papers in Europe PMC - 09Cumming SA4 papers · 2023
Department of Psychiatry (E.v.d.P., T.R.K., P.N.), Department of Radiology (V.M.), and Department of Neurology (L.G.), University of Iowa Hospitals and Clinics; and Institute of Molecular, Cell and Systems Biology (S.A.C., D.M.), University of Glasgow, Scotland, United Kingdom.
Papers in Europe PMC - 10Long JD4 papers · 2023
Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 63 trials are registered for myotonic dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
63 interventional trials matched myotonic dystrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: myotonic dystrophy
63
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05481879·RECRUITING·Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT06596850·NOT YET RECRUITING·Wheelchair Skills Training for People with ARSACS and DM1
Conditions: Wheelchair Mobility · Manual Wheelchair Skills Training · ARSACS · Myotonic Dystrophy Type 1·Matched via name phrase
- NCT07072676·ENROLLING BY INVITATION·The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Conditions: Inclusion Body Myositis · Myotonic Dystrophy 1 · Myotonic Dystrophy 2 · Facio-Scapulo-Humeral Dystrophy·Matched via name phrase
- NCT06549400·ENROLLING BY INVITATION·An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
Conditions: Myotonic Dystrophy·Matched via name phrase
- NCT06316778·RECRUITING·Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
Conditions: Myotonic Dystrophy Type 1 · Urinary Incontinence·Matched via name phrase
- NCT06185764·RECRUITING·A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT06926621·ENROLLING BY INVITATION·A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Conditions: Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT06667453·RECRUITING·A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Conditions: Myotonic Dystrophy 1·Matched via name phrase
- NCT07136844·RECRUITING·Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Conditions: Neuromuscular Diseases · Obesity (Disorder) · Myotonic Dystrophy 1 · Myasthenic Syndrome·Matched via name phrase
- NCT06716931·RECRUITING·Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
Conditions: Myotonic Dystrophy 2·Matched via name phrase
- NCT06809049·RECRUITING·Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)
Conditions: Myotonic Dystrophy, Congenital · Myotonic Dystrophy, Type 1 (DM1) · Myotonic Dystrophy Type 1 · Myotonic Dystrophy Type 1 (DM1)·Matched via name phrase
- NCT07321977·RECRUITING·Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
Conditions: Spinal Muscular Atrophy (SMA) · Charcot-Marie-Tooth · Muscular Dystrophy · Myotonic Dystrophy·Matched via name phrase
- NCT05004129·RECRUITING·Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Conditions: Congenital Myotonic Dystrophy·Matched via name phrase
- NCT07486934·RECRUITING·Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Conditions: Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Steinert Disease·Matched via name phrase
- NCT05982119·RECRUITING·Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Conditions: Duchenne Muscular Dystrophy · Fascioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy 1 · Charcot-Marie-Tooth·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Adult-onset Steinert myotonic dystrophy" OR "Adult-onset Steinert disease" OR "Adult-onset myotonic dystrophy type 1"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Adult-onset Steinert myotonic dystrophy" OR "Adult-onset Steinert disease" OR "Adult-onset myotonic dystrophy type 1"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myotonic dystrophy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T18:47:53.362Z
